Table 1. Relationship between serum CA72-4 levels and clinicopathological variables (n=113).
| serum CA72-4 levels | P | |||
|---|---|---|---|---|
| Variables | Total (n) | CA 72-4≤6.9 U/mL (n=71) | CA 72-4>6.9 U/mL (n=42) | |
| Gender | ||||
| Male | 71 | 41 (57.7%) | 30 (42.3%) | 0.146 |
| Female | 42 | 30 (71.4%) | 12 (28.6%) | |
| Age | ||||
| <65 | 80 | 52 (65.0%) | 28 (35.0%) | 0.458 |
| ≥65 | 33 | 19 (57.6%) | 14 (42.4%) | |
| Smoking status | ||||
| Never | 58 | 44 (75.9%) | 14 (24.1%) | 0.003 |
| Current/ever | 55 | 27 (49.1%) | 28 (50.9%) | |
| Tumor location | ||||
| Head | 57 | 35 (61.4%) | 22 (38.6%) | 0.322 |
| Body and tail | 56 | 36 (64.3%) | 20 (35.7%) | |
| T stage | ||||
| T1-2 | 29 | 16 (55.2%) | 13 (44.8%) | 0.322 |
| T3-4 | 84 | 55 (65.5%) | 29 (34.5%) | |
| N stage | ||||
| N0 | 60 | 47 (78.3%) | 13 (21.7%) | <0.001 |
| N1 | 53 | 24 (45.3%) | 29 (54.7%) | |
| Treatment Response | ||||
| CR+PR | 37 | 27 (73.0%) | 10 (27.0%) | 0.120 |
| SD+PD | 76 | 44 (57.6%) | 32 (42.1%) | |